Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies

Karlijn A. Wouters, Leontien C M Kremer, Tracie L Miller, Eugene H. Herman, Steven E Lipshultz

Research output: Contribution to journalArticle

321 Citations (Scopus)

Abstract

Over the last 40 years, great progress has been made in treating childhood and adult cancers. However, this progress has come at an unforeseen cost, in the form of emerging long-term effects of anthracycline treatment. A major complication of anthracycline therapy is its adverse cardiovascular effects. If these cardiac complications could be reduced or prevented, higher doses of anthracyclines could potentially be used, thereby further increasing cancer cure rates. Moreover, as the incidence of cardiac toxicity resulting in congestive heart failure or even heart transplantation dropped, the quality and extent of life for cancer survivors would improve. We review the proposed mechanisms of action of anthracyclines and the consequences associated with anthracycline treatment in children and adults. We summarise the most promising current strategies to limit or prevent anthracycline-induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening.

Original languageEnglish
Pages (from-to)561-578
Number of pages18
JournalBritish Journal of Haematology
Volume131
Issue number5
DOIs
StatePublished - Dec 1 2005

Fingerprint

Anthracyclines
Neoplasms
Heart Transplantation
Cardiomyopathies
Survivors
Therapeutics
Heart Failure
Quality of Life
Costs and Cost Analysis
Incidence

Keywords

  • Anthracyclines
  • Cancer
  • Cardioprotective agents
  • Myocardial damage
  • Prevention

ASJC Scopus subject areas

  • Hematology

Cite this

Protecting against anthracycline-induced myocardial damage : A review of the most promising strategies. / Wouters, Karlijn A.; Kremer, Leontien C M; Miller, Tracie L; Herman, Eugene H.; Lipshultz, Steven E.

In: British Journal of Haematology, Vol. 131, No. 5, 01.12.2005, p. 561-578.

Research output: Contribution to journalArticle

Wouters, Karlijn A. ; Kremer, Leontien C M ; Miller, Tracie L ; Herman, Eugene H. ; Lipshultz, Steven E. / Protecting against anthracycline-induced myocardial damage : A review of the most promising strategies. In: British Journal of Haematology. 2005 ; Vol. 131, No. 5. pp. 561-578.
@article{7c8e0bdb61e14171a700fa5b5a922480,
title = "Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies",
abstract = "Over the last 40 years, great progress has been made in treating childhood and adult cancers. However, this progress has come at an unforeseen cost, in the form of emerging long-term effects of anthracycline treatment. A major complication of anthracycline therapy is its adverse cardiovascular effects. If these cardiac complications could be reduced or prevented, higher doses of anthracyclines could potentially be used, thereby further increasing cancer cure rates. Moreover, as the incidence of cardiac toxicity resulting in congestive heart failure or even heart transplantation dropped, the quality and extent of life for cancer survivors would improve. We review the proposed mechanisms of action of anthracyclines and the consequences associated with anthracycline treatment in children and adults. We summarise the most promising current strategies to limit or prevent anthracycline-induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening.",
keywords = "Anthracyclines, Cancer, Cardioprotective agents, Myocardial damage, Prevention",
author = "Wouters, {Karlijn A.} and Kremer, {Leontien C M} and Miller, {Tracie L} and Herman, {Eugene H.} and Lipshultz, {Steven E}",
year = "2005",
month = "12",
day = "1",
doi = "10.1111/j.1365-2141.2005.05759.x",
language = "English",
volume = "131",
pages = "561--578",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Protecting against anthracycline-induced myocardial damage

T2 - A review of the most promising strategies

AU - Wouters, Karlijn A.

AU - Kremer, Leontien C M

AU - Miller, Tracie L

AU - Herman, Eugene H.

AU - Lipshultz, Steven E

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Over the last 40 years, great progress has been made in treating childhood and adult cancers. However, this progress has come at an unforeseen cost, in the form of emerging long-term effects of anthracycline treatment. A major complication of anthracycline therapy is its adverse cardiovascular effects. If these cardiac complications could be reduced or prevented, higher doses of anthracyclines could potentially be used, thereby further increasing cancer cure rates. Moreover, as the incidence of cardiac toxicity resulting in congestive heart failure or even heart transplantation dropped, the quality and extent of life for cancer survivors would improve. We review the proposed mechanisms of action of anthracyclines and the consequences associated with anthracycline treatment in children and adults. We summarise the most promising current strategies to limit or prevent anthracycline-induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening.

AB - Over the last 40 years, great progress has been made in treating childhood and adult cancers. However, this progress has come at an unforeseen cost, in the form of emerging long-term effects of anthracycline treatment. A major complication of anthracycline therapy is its adverse cardiovascular effects. If these cardiac complications could be reduced or prevented, higher doses of anthracyclines could potentially be used, thereby further increasing cancer cure rates. Moreover, as the incidence of cardiac toxicity resulting in congestive heart failure or even heart transplantation dropped, the quality and extent of life for cancer survivors would improve. We review the proposed mechanisms of action of anthracyclines and the consequences associated with anthracycline treatment in children and adults. We summarise the most promising current strategies to limit or prevent anthracycline-induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening.

KW - Anthracyclines

KW - Cancer

KW - Cardioprotective agents

KW - Myocardial damage

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=33644806519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644806519&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2005.05759.x

DO - 10.1111/j.1365-2141.2005.05759.x

M3 - Article

C2 - 16351632

AN - SCOPUS:33644806519

VL - 131

SP - 561

EP - 578

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -